Simbiótico de última geração em indivíduos com sobrepeso ou obesidade
Suplementação com um simbiótico de última geração em indivíduos com sobrepeso ou obesidade: um ensaio clínico triplo-cego randomizado controlado
This study plans to evaluate the effect of consuming a symbiotic (probiotic + prebiotic) for 3 months on body weight, body composition, glucose sensitivity, and psychological parameters, as well as on gut and blood microbial composition. Synbiotic consumption is preceded by a 3-day antibiotic course to help ensure the opening of new niches (houses) for the upcoming beneficial bacteria.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
This is a triple-blinded, randomized clinical trial in which participants will be allocated to one of two groups: 1) 3-day antibiotic followed by synbiotic consumption for 3 months or 2) 3-day antibiotic followed by placebo consumption for 3 months.
Blood and stool samples will be collected before the antibiotic, and before and after the symbiotic intervention in both groups.
Gut microbial composition will be analyzed through whole genome sequencing and blood microbial composition through 16S rRNA.
Glucose sensitivity will be measured through fasting glucose, fasting insulin, and HbA1c.
Body composition through DXA and BodPod will be measured before and after the symbiotic intervention.
Psychological questionnaires such as the Beck Anxiety and the Beck Depression Inventories, as well as the RED-9 questionnaire to respectively measure anxiety, depression, and food cravings, will be applied before and after the symbiotic intervention.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Texas
-
Fort Worth, Texas, Estados Unidos, 76129
- Texas Christian University, Rickel Building
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- be between 18-50 years of age
- have a BMI between 25.0-40.0
Exclusion Criteria:
- are following a vegetarian, vegan, carnivore, or keto diet
- currently taking metformin, GLP-1 agonists, insulin, or fiber
- have taken antiacids, laxatives, probiotics, or medication that affects your immune system in the past month
- pregnant, planning pregnancy during the study period, or lactating
- have a history of inflammatory bowel disease, colon cancer, or chronic polyps
- have been diagnosed with type 1 or type 2 diabetes
- have active cancer
- are currently participating in a weight loss intervention (dietetic or medication)
- have used antibiotics, antifungals, or antivirals in the past 3 months
- have had a history of recent (within 30 days) diarrhea illness
- have a known allergy to any component of the study product
- have had an acute inflammatory infection or inflammatory condition in the past 4 weeks
- have had >10% weight variation in the past 6 months
- have had any bariatric surgery
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Synbiotic Group
They will receive a 3-day antibiotic (Vancomycin 500 mg/3 times/day), followed by a 3-month symbiotic. The synbiotic that will be used in this trial contains the oligosaccharide-degrading probiotics, Akkermansia muciniphila and Bifidobacterium infantis; butyrate producers such as Clostridium beijerinckii, Anaerobutyricum hallii, and Clostridium butyricum; and chicory-derived inulin, a prebiotic dietary fiber. |
WBF-038: Noninfectious and nonhazardous lyophilized commensal bacteria (probiotics). Contains no genetically modified organisms (GMOs) and contains no animal ingredients or by-products, and were originally isolated from human sources. The (probiotic) strains are grown in a FDA registered food facility, adhering to Good Manufacturing Practice (GMP) conditions. Probiotic Ingredients: Clostridium butyricum WBSTR-0006, Clostridium beijerinckii WB-STR-0005, Anaerobutyricum hallii WB-STR-0008, Akkermansia muciniphila WBSTR-0001, and Bifidobacterium infantis The product also contains: Chicory inulin and oligofructose (prebiotic fiber), hypromellose (vegetarian capsule), fruit & vegetable juice (coloring agent), magnesium stearate and silica (flow agent for encapsulation)
Outros nomes:
|
|
Comparador de Placebo: Placebo Group
They will receive a 3-day antibiotic (Vancomycin 500 mg/3 times/day), followed by a 3-month placebo. |
Ingredients: Chicory inulin and oligofructose (prebiotic fiber, hypromellose (vegetarian capsule), fruit & vegetable juice (coloring agent), magnesium stearate and silica (flow agent for encapsulation).
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Total Body Fat Mass through DXA (percentage)
Prazo: These analyses will take place right before and right after the 3-month synbiotic/placebo intervention.
|
We will measure body fat mass by using DXA analysis. |
These analyses will take place right before and right after the 3-month synbiotic/placebo intervention.
|
|
Total Body Fat Mass through BodPod (percentage)
Prazo: These analyses will take place right before and right after the 3-month synbiotic/placebo intervention.
|
We will measure body fat mass by using BodPod analysis. |
These analyses will take place right before and right after the 3-month synbiotic/placebo intervention.
|
|
Fat Mass to Height (kg/m2)
Prazo: These analyses will take place right before and right after the 3-month synbiotic/placebo intervention.
|
We will measure body fat mass by using DXA analysis. |
These analyses will take place right before and right after the 3-month synbiotic/placebo intervention.
|
|
Fat Mass (kg)
Prazo: These analyses will take place right before and right after the 3-month synbiotic/placebo intervention.
|
We will measure body fat mass by using BodPod analysis. |
These analyses will take place right before and right after the 3-month synbiotic/placebo intervention.
|
|
Body Lean Mass to Height (kg/m2)
Prazo: These analyses will take place right before and right after the 3-month synbiotic/placebo intervention.
|
We will measure body lean mass by using DXA analysis. |
These analyses will take place right before and right after the 3-month synbiotic/placebo intervention.
|
|
Fat Free Mass (%)
Prazo: These analyses will take place right before and right after the 3-month synbiotic/placebo intervention.
|
We will measure body lean mass by using BodPod analysis. |
These analyses will take place right before and right after the 3-month synbiotic/placebo intervention.
|
|
Fat Free Mass (Kg)
Prazo: These analyses will take place right before and right after the 3-month synbiotic/placebo intervention.
|
We will measure body lean mass by using BodPod analysis. |
These analyses will take place right before and right after the 3-month synbiotic/placebo intervention.
|
|
Visceral Fat Volume (cm3)
Prazo: These analyses will take place right before and right after the 3-month synbiotic/placebo intervention.
|
We will measure body visceral mass by using DXA and BodPod analysis. |
These analyses will take place right before and right after the 3-month synbiotic/placebo intervention.
|
|
Visceral Fat Mass (grams)
Prazo: These analyses will take place right before and right after the 3-month synbiotic/placebo intervention.
|
We will measure body visceral mass by using DXA and BodPod analysis. |
These analyses will take place right before and right after the 3-month synbiotic/placebo intervention.
|
|
Fasting Glucose (mg/dL)
Prazo: Blood samples will be taken before the antibiotic, before the synbiotic/placebo, and right after the 3-month synbiotic/placebo intervention.
|
We will measure fasting glucose after a 12h fast. |
Blood samples will be taken before the antibiotic, before the synbiotic/placebo, and right after the 3-month synbiotic/placebo intervention.
|
|
Fasting Insulin (mIU/L)
Prazo: Blood samples will be taken before the antibiotic, before the synbiotic/placebo, and right after the 3-month synbiotic/placebo intervention.
|
We will measure fasting insulin after a 12h fast. |
Blood samples will be taken before the antibiotic, before the synbiotic/placebo, and right after the 3-month synbiotic/placebo intervention.
|
|
HbA1c (%)
Prazo: Blood samples will be taken before the antibiotic, before the synbiotic/placebo, and right after the 3-month synbiotic/placebo intervention.
|
We will measure HbA1c after a 12h fast. |
Blood samples will be taken before the antibiotic, before the synbiotic/placebo, and right after the 3-month synbiotic/placebo intervention.
|
|
Anxiety (number in 0-63 scale)
Prazo: These questionnaires will be applied right before and right after the 3-month synbiotic/placebo intervention.
|
We will measure anxiety by using the Beck Anxiety inventory. The higher the number, the higher the anxiety levels. |
These questionnaires will be applied right before and right after the 3-month synbiotic/placebo intervention.
|
|
Depression (number in 0-63 scale)
Prazo: These questionnaires will be applied right before and right after the 3-month synbiotic/placebo intervention.
|
We will measure depression by using the Beck Depression inventory. The higher the number, the higher the depression. |
These questionnaires will be applied right before and right after the 3-month synbiotic/placebo intervention.
|
|
Food cravings (number in 0-52 scale)
Prazo: These questionnaires will be applied right before and right after the 3-month synbiotic/placebo intervention.
|
We will measure food cravings by using the Reward-based Eating Drive questionnaire (RED-9). The higher the number, the higher the cravings. |
These questionnaires will be applied right before and right after the 3-month synbiotic/placebo intervention.
|
|
Gut Microbial Composition (depending on funding availability at the time of analysis)
Prazo: Stool samples will be collected right before the antibiotic, right before the synbiotic/placebo intervention, and right after the 3-month synbiotic/placebo intervention.
|
We plan to measure gut microbial composition by performing whole metagenome sequencing previously stored in Zymo stool collection tubes. |
Stool samples will be collected right before the antibiotic, right before the synbiotic/placebo intervention, and right after the 3-month synbiotic/placebo intervention.
|
|
Blood Microbial Composition (depending on funding availability at the time of analysis)
Prazo: Blood samples will be collected right before the antibiotic, right before the synbiotic/placebo intervention, and right after the 3-month synbiotic/placebo intervention.
|
We plan to measure blood microbial composition by performing 16S rRNA in blood samples previously stored in Zymo blood collection tubes. |
Blood samples will be collected right before the antibiotic, right before the synbiotic/placebo intervention, and right after the 3-month synbiotic/placebo intervention.
|
|
Body Weight (kg)
Prazo: Measurements will take place at each of the 3 visits: right before the antibiotic, right before the synbiotic/placebo, and right after the 3-month synbiotic/placebo intervention.
|
Body weight will be measured with a calibrated scale. |
Measurements will take place at each of the 3 visits: right before the antibiotic, right before the synbiotic/placebo, and right after the 3-month synbiotic/placebo intervention.
|
|
Body Height (meters)
Prazo: Measurement will take place at the first visit.
|
Body height will be measured with a stadiometer. |
Measurement will take place at the first visit.
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Elisa Marroquin, Ph.D., Texas Christian University
Publicações e links úteis
Publicações Gerais
- Depommier C, Everard A, Druart C, Plovier H, Van Hul M, Vieira-Silva S, Falony G, Raes J, Maiter D, Delzenne NM, de Barsy M, Loumaye A, Hermans MP, Thissen JP, de Vos WM, Cani PD. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med. 2019 Jul;25(7):1096-1103. doi: 10.1038/s41591-019-0495-2. Epub 2019 Jul 1.
- Perraudeau F, McMurdie P, Bullard J, Cheng A, Cutcliffe C, Deo A, Eid J, Gines J, Iyer M, Justice N, Loo WT, Nemchek M, Schicklberger M, Souza M, Stoneburner B, Tyagi S, Kolterman O. Improvements to postprandial glucose control in subjects with type 2 diabetes: a multicenter, double blind, randomized placebo-controlled trial of a novel probiotic formulation. BMJ Open Diabetes Res Care. 2020 Jul;8(1):e001319. doi: 10.1136/bmjdrc-2020-001319.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 2023-345
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
De-identified participant-level data can be shared only after authors and co-authors have published the material of their interest.
Prazo de Compartilhamento de IPD
Data will be available only after authors and co-authors have published the material of their interest.
Critérios de acesso de compartilhamento IPD
Not available at this point. Recruitment has not started.
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .